Author:
Otum Christian C.,Rivière Emmanuel,Barnard Monique,Loubser Johannes,Williams Monique J.,Streicher Elizabeth M.,Van Rie Annelies,Warren Robin M.,Klopper Marisa
Abstract
AbstractMolecular detection of bedaquiline resistant tuberculosis is challenging as only a small proportion of mutations in candidate bedaquiline resistance genes have been statistically associated with phenotypic resistance. We introduced two mutations, atpE Ile66Val and Rv0678 Thr33Ala, in the Mycobacterium tuberculosis H37Rv reference strain using homologous recombineering or recombination to investigate the phenotypic effect of these mutations. The genotype of the resulting strains was confirmed by Sanger- and whole genome sequencing, and bedaquiline susceptibility was assessed by minimal inhibitory concentration (MIC) assays. The impact of the mutations on protein stability and interactions was predicted using mutation Cutoff Scanning Matrix (mCSM) tools. The atpE Ile66Val mutation did not elevate the MIC above the critical concentration (MIC 0.25–0.5 µg/ml), while the MIC of the Rv0678 Thr33Ala mutant strains (> 1.0 µg/ml) classifies the strain as resistant, confirming clinical findings. In silico analyses confirmed that the atpE Ile66Val mutation minimally disrupts the bedaquiline-ATP synthase interaction, while the Rv0678 Thr33Ala mutation substantially affects the DNA binding affinity of the MmpR transcriptional repressor. Based on a combination of wet-lab and computational methods, our results suggest that the Rv0678 Thr33Ala mutation confers resistance to BDQ, while the atpE Ile66Val mutation does not, but definite proof can only be provided by complementation studies given the presence of secondary mutations.
Funder
Fonds Wetenschappelijk Onderzoek
European and Developing Countries Clinical Trials Partnership
South African Medical Research Council
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Cox, E. & Laessig, K. FDA approval of bedaquiline: The benefit-risk balance for drug-resistant tuberculosis. N. Engl. J. Med. 371(8), 689–691 (2014).
2. Rapid Communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). https://www.who.int/publications/i/item/WHO-CDS-TB-2018.18. Accessed 27 Dec 2022.
3. Andries, K. et al. Acquired resistance of Mycobacterium tuberculosis to Bedaquiline. PLoS ONE 9(7), e102135. https://doi.org/10.1371/journal.pone.0102135 (2014).
4. Bloemberg, G. V. et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N. Engl. J. Med. 373(20), 1986–1988 (2015).
5. Somoskovi, A., Bruderer, V., Hömke, R., Bloemberg, G. V. & Böttger, E. C. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur. Respir. J. 45(2), 554–557 (2015).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献